Value through Innovation28 April 2015

Boehringer Ingelheim Press Releases

See the latest Boehringer Ingelheim news releases. To quickly find all news releases on a specific topic, please use the fulltext search.

Press Release Archive


Boehringer Ingelheim announces interim results from a Phase III trial in HIV patients co-infected with chronic hepatitis C

- For media outside of the U.S.A., UK and Canada only

Rare disease day: Boehringer Ingelheim announces initiation of pivotal trial investigating volasertib* in patients with acute myeloid leukaemia

- For NON-US media only

Healthcare Innovation World Cup: Call for Breakthrough Ideas to Tackle Diabetes


Phase III results: tiotropium* Respimat® is effective in symptomatic asthma patients irrespective of their allergic status


New findings from two studies support substantial benefit of Pradaxa® for prevention of recurrent deep vein thrombosis and pulmonary embolism

- For Non-US, Non-UK & Non-Canadian Media Only

Preventing disease: One billion pigs vaccinated with Ingelvac CircoFLEX®


FDA Advisory Committee Recommends Approval for Boehringer Ingelheim’s Olodaterol* for Maintenance Treatment of COPD

- For Media outside the U.S. and UK

Boehringer Ingelheim and Ashoka Changemakers Launch Competition to Find Business Models that Transform Health Systems


Boehringer Ingelheim and the EFSD call for grant applications in diabetes research


Boehringer Ingelheim enrols first patients in pivotal Phase III interferon-free hepatitis C trial programme

- For media outside of the U.S.A., UK and Canada only

U.S. FDA Grants Priority Review to Boehringer Ingelheim’s Afatinib* NDA for EGFR Mutation-Positive Advanced NSCLC

- For NON-U.S. Media Only

Boehringer Ingelheim and Eli Lilly and Company announce positive top-line pivotal Phase III data results for empagliflozin

- EX US & UK. Medical Media Only.

Lilly reassumes sole worldwide development and commercialization rights for novel basal insulin analog


Boehringer Ingelheim receives EU approval for Metacam® for the relief of pain following dehorning in calves


Boehringer Ingelheim discontinues Phase II trial in patients with artificial heart valves

- For Non-US, Non-UK & Non-Canadian Media Only

Boehringer Ingelheim to initiate Phase III study in leukaemia with its compound volasertib* based on positive Phase II results

- For NON-US media only

Treatment with Pradaxa® associated with better patient outcomes after a major bleeding event compared to warfarin

- For Non-US, Non-UK & Non-Canadian Media Only

Boehringer Ingelheim and Apexigen sign manufacturing agreement for process development and early stage clinical supply